Mid-term report 2013 - The European LeukemiaNet

European LeukemiaNet Midterm Report, 08-RNP-071
demographic paper which will include the impact of the new IPSS-R.
2) The fifth international ELN workshop of FCM in MDS,Amsterdam, Netherlands
October 26‐27, 2012
3) Progress of the Trial Platform: EMSCO and planned trial(s)
The ELN-based MDS clinical trial coordinating office (EMSCO) has been established in
Dresden. The first trial in France and Germany is expected to start before the end of 2013.
4) ELN diagnostic and therapeutic guidelines and new plans, including specific guidelines for
allogeneic SCT in MDS
The manuscript has been submitted to Blood and it is under revision after having received
the comments of the reviewers.
2.1.9. WP9 (MPD):
Projects:
Clinically relevant end-points in contemporary trials for Ph-neg classical MPNs: A joint project
of the ELN and IWG-MRT Groups
The rationale of this project is that the selection of best variables for measuring benefits
or harms of new interventions in Philadelphia negative classic MPNs is a complex and
open to debate task. There is a major need to develop clearly defined endpoints to
support claims of efficacy of therapies for MPNs. These endpoints need to be developed
and utilized by investigators leading clinical trials in MPNs. The goal of this project is to
provide guidance in the definition of clinically relevant end-points that can expedite new
drug approvals for MPNs in the appropriate trial design settings.
Registries:
A new registry of patients with MPD and splanchnic vein thrombosis (Budd-Chiari syndrome,
portal or mesenteric vein thrombosis) has been launched in 2013.
A new project was presented in 2013 and was opened in May 2013 to collect the cases of
cerebral venous thrombosis in patients with MPD.
The registry of pregnancies in patients with MPD was closed for inclusions in 2013? And the
analysis for a final report and publication is ongoing.
A MPN&MPNr-EuroNet registry is in planning.
Recommendations:
Several recommendations have been released on behalf of the ELN, as described in the
appendix 7.5.1.
The leading project for recommendation in 2013 is the definition of resistance and
intolerance to ruxolitinib.
Another consensus conference is ongoing in 2013 to define and harmonize
histomorphological response criteria to JAK inhibitors. Two face-to-face meetings have been
organized and the redaction of the final consensus is in progress, with a publication planed
for Q3 2013.
2.1.10. WP10 (Diagnostics):
WP10 aims at pursuing the exploration of the best methods for diagnosis and MRD detection
in morphology and flow cytometry.
The morphology faculty, driven by Pr Gina Zini, still works at implementing the atlas of bone
marrow cells morphology, accessible on the ELN Website.
In flow, recommendations about accreditation of the flow cytometry laboratory are in
progress. Part of this will soon be in press in Cytometry Part B, as the result of an
international workshop where WP10 members participated. Guidelines have been issued in
France and discussed in Mannheim in February. The February 2013 annual meeting of the
8